Stopping Counterfeit Medicines Online

12.02.13 | By

Fake medicines put patients and the public at risk. In the U.S. almost all fake medicines enter the drug supply through purchases over the internet. This is a pervasive problem all around the world.

A Time to Give Thanks

11.22.13 | By

With Thanksgiving right around the corner, it’s a good opportunity to reflect on what we’re thankful for and the progress we’ve made this year. For the biopharmaceutical research companies discovering new medicines, we're proud of our advancements that have helped develop new treatments and ensured the health and safety of our patients.

Question Submission Form

PhRMA Innovation Act Letter

Early Detection for Prostate Cancer

11.19.13 | By

Prostate cancer is the second-most common form of cancer affecting men. In 2013, it is estimated that nearly 240,000 American men will be diagnosed with the disease and 29,000 will die from it.

PhRMA Statement: Drug Quality and Security Act

Washington, D.C. (November 18, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J Castellani issued the following statement:

“PhRMA is pleased that the Senate has passed the Drug Quality and Security Act and that the bill will now head to the White House for President Obama’s signature.

PhRMA Statement

WASHINGTON, D.C. (November 17, 2013) Pharmaceutical Research and Manufacturers of America Senior Vice President of Communications Matthew Bennett made the following statement today: 

Week in Review: Commitment Matters

11.15.13 | By

The biopharmaceutical industry has made significant progress over the years, with innovative new treatments improving outcomes for some of the nation’s most debilitating diseases.

AHA/ACC Guidelines

11.15.13 | By

The newly released American Heart Association (AHA) and American College of Cardiology (ACC) Guidelines on the Treatment of Blood Cholesterol and Lifestyle Management to Reduce Atherosclerotic Cardiovascular Risk in Adults have received a great deal of attention over the last couple days and are certain to stimulate further discussion as physicians and patients alike integrate the new rec

Rx Response

11.15.13 | By

Guest Post from Erin Mullen, PhRMA Associate VP and Director of Rx Response


Subscribe to RSS - Opinion